资料显示，咸亨国际科技股份有限公司位于浙江省杭州市拱墅区星璜巷101号咸亨科技大厦，成立日期 2008年4月11日，上市日期2021年7月20日，公司主营业务涉及经销国内外知名工器具、仪器仪表类 MRO并生产销售自有品牌产品。主营业务收入构成为：工器具类71.80%，仪器仪表类22.21%，技术服 务5.93%，其他(补充)0.04%，其他0.02%。 咸亨国际所属申万行业为：机械设备-通用设备-仪器仪表。所属概念板块包括：职业教育、小盘、应急 管理、特高压、电力物联网等。 截至9月30日，咸亨国际股东户数1.23万，较上期减少8.65%；人均流通股32987股，较上期增加9.47%。 2025年1月-9月，咸亨国际实现营业收入26.95亿元，同比增长35.47%；归母净利润1.28亿元，同比增长 32.45%。 机构持仓方面，截止2025年9月30日，咸亨国际十大流通股东中，交银趋势混合A（519702）退出十大 流通股东之列。 11月26日，咸亨国际盘中上涨2.08%，截至10:30，报18.64元/股，成交2299.27万元，换手率0.31%，总 市值76.48亿元。 资金流向方面，主力资金净流入38. ...

Core Points - The stock price of Chendian International increased by 2.17% on November 26, reaching 8.94 CNY per share, with a market capitalization of 3.308 billion CNY [1] - The company has seen a year-to-date stock price increase of 39.04%, with recent gains of 2.29% over the last five trading days and 17.02% over the last twenty days [1] - Chendian International's main business segments include electricity production and sales (83.88% of revenue), water supply (9.85%), and gas production (5.88%) [1] Financial Performance - For the period from January to September 2025, Chendian International reported a revenue of 3.079 billion CNY, a year-on-year decrease of 7.16%, while net profit attributable to shareholders increased by 33.93% to 80.9675 million CNY [2] - The company has distributed a total of 275 million CNY in dividends since its A-share listing, with 21.796 million CNY distributed over the past three years [3] Shareholder Information - As of November 20, the number of shareholders for Chendian International was 18,400, a decrease of 1.01% from the previous period, with an average of 20,125 circulating shares per shareholder, an increase of 1.02% [2]

Core Viewpoint - Spring Medical has shown significant stock price growth of 95.67% year-to-date, despite a recent decline in the last five and twenty trading days [2]. Company Overview - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, is based in Tongzhou District, Beijing. The company specializes in the research, production, and sales of implantable orthopedic medical devices, primarily focusing on joint prosthetics and spinal implants [2]. - The company's main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal fixation systems. Its products are exported to various regions including Asia, South America, Africa, Oceania, and Europe [2]. - The revenue composition of Spring Medical is predominantly from medical device products (99.89%), with a minor contribution from other sources (0.11%) [2]. Financial Performance - As of September 30, 2025, Spring Medical reported a revenue of 756 million yuan, reflecting a year-on-year growth of 48.75%. The net profit attributable to shareholders was 192 million yuan, marking a substantial increase of 213.21% [3]. - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [4]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 4.12% to 6,164, while the average number of circulating shares per person decreased by 3.95% to 46,906 shares [3]. - Notable institutional shareholders include Hong Kong Central Clearing Limited, which is the fourth-largest shareholder with 2.9585 million shares, and China Europe Economic Growth Mixed A Fund, which is the fifth-largest with 2.8326 million shares, both being new entrants [4].

Core Viewpoint - The stock price of Jianzhijia has shown a slight increase of 2.04% on November 26, 2023, with a current price of 20.52 CNY per share, despite a year-to-date decline of 6.79% [1] Company Overview - Jianzhijia Pharmaceutical Chain Group Co., Ltd. is located in Kunming, Yunnan Province, and was established on September 27, 2004. The company was listed on December 1, 2020. Its main business involves the retail of health products, including pharmaceuticals, health foods, personal care products, and daily consumables [1] - The revenue composition of Jianzhijia includes: prescription and non-prescription drugs (72.60%), with non-prescription drugs at 39.64% and prescription drugs at 32.96%. Other segments include medical devices (7.44%), other (5.52%), convenience products (5.05%), health foods (4.84%), traditional Chinese medicine (3.28%), personal care products (1.18%), and health check services (0.09%) [1] Financial Performance - For the period from January to September 2025, Jianzhijia reported a revenue of 6.549 billion CNY, a year-on-year decrease of 2.77%. The net profit attributable to the parent company was 101 million CNY, reflecting a slight decrease of 0.22% year-on-year [2] - Since its A-share listing, Jianzhijia has distributed a total of 715 million CNY in dividends, with 473 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, Jianzhijia had 15,100 shareholders, a slight decrease of 0.04% from the previous period. The average circulating shares per person increased by 0.04% to 10,240 shares [2] - Among the top ten circulating shareholders, Rongtong Health Industry Flexible Allocation Mixed A/B holds 7.1 million shares, remaining unchanged from the previous period. Meanwhile, Guangfa Innovation Upgrade Mixed has exited the top ten list [3]

Core Viewpoint - Shanghai Kaibao's stock has shown a mixed performance in recent trading sessions, with a year-to-date increase of 7.57% and a recent decline over the past 60 days [1][2] Group 1: Stock Performance - As of November 26, Shanghai Kaibao's stock price increased by 2.03%, reaching 6.54 CNY per share, with a trading volume of 97.67 million CNY and a turnover rate of 1.64% [1] - The stock has experienced a 3.32% increase over the last five trading days and a 6.00% increase over the last 20 days, while it has decreased by 3.82% over the last 60 days [1] - The company has appeared on the "龙虎榜" (a list of stocks with significant trading activity) once this year, with a net buy of 2.04 million CNY on January 6 [1] Group 2: Financial Performance - For the period from January to September 2025, Shanghai Kaibao reported a revenue of 819 million CNY, a year-on-year decrease of 26.95%, and a net profit attributable to shareholders of 187 million CNY, down 13.83% year-on-year [2] - The company has distributed a total of 1.55 billion CNY in dividends since its A-share listing, with 303 million CNY distributed over the past three years [3] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Shanghai Kaibao was 49,300, a decrease of 6.04% from the previous period, with an average of 18,586 shares held per shareholder, an increase of 6.43% [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 6.99 million shares, an increase of 750,100 shares from the previous period [3]

Core Viewpoint - Jinhua Co., Ltd. has experienced a stock price increase of 13.08% year-to-date, with significant gains in recent trading periods, indicating positive market sentiment despite a slight decline on November 26 [2]. Group 1: Stock Performance - As of November 26, Jinhua's stock price was reported at 8.80 CNY per share, with a trading volume of 77.9 million CNY and a turnover rate of 2.34%, resulting in a total market capitalization of 3.285 billion CNY [1]. - The stock has seen a price increase of 8.51% over the last five trading days, 16.87% over the last 20 days, and 11.39% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Jinhua achieved a revenue of 384 million CNY, reflecting a year-on-year decrease of 8.36%, while the net profit attributable to shareholders was 34.48 million CNY, showing a year-on-year increase of 12.06% [2]. - The company's main business revenue is derived from pharmaceutical sales, accounting for 99.71% of total revenue, with other income contributing 0.29% [2]. Group 3: Shareholder Information - As of September 30, the number of shareholders for Jinhua was 20,100, a decrease of 2.22% from the previous period, with an average of 18,574 circulating shares per shareholder, which is an increase of 2.27% [2]. Group 4: Dividend Information - Since its A-share listing, Jinhua has distributed a total of 118 million CNY in dividends, with 10.58 million CNY distributed over the past three years [3].

Core Viewpoint - Ling Steel Co., Ltd. has shown a mixed performance in stock price and financial metrics, with a notable increase in stock price year-to-date but a decline in recent trading days, alongside a significant drop in revenue for the first nine months of 2025 [1][2]. Financial Performance - As of September 30, 2025, Ling Steel reported a revenue of 11.759 billion yuan, a year-on-year decrease of 15.31% [2]. - The company experienced a net profit of -844 million yuan, which represents a year-on-year increase of 38.12% [2]. - Cumulative cash dividends since the A-share listing amount to 1.758 billion yuan, with no dividends paid in the last three years [3]. Stock Market Activity - On November 26, 2025, Ling Steel's stock price increased by 2.20%, reaching 2.32 yuan per share, with a trading volume of 19.3931 million yuan and a turnover rate of 0.30% [1]. - The stock has appreciated by 29.61% year-to-date, but has seen a decline of 5.69% over the last five trading days [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with a net buy of 5.4032 million yuan on July 4 [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 48,400, a rise of 10.78% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 9.73% to 58,190 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Guotai CSI Steel ETF, with the former increasing its holdings by 2.7707 million shares [3]. Company Overview - Ling Steel, established on May 4, 1994, and listed on May 11, 2000, is primarily engaged in the production and sale of metallurgical products, with steel sales accounting for 91.53% of its main business revenue [1]. - The company operates within the steel industry, specifically in the sub-sector of ordinary steel and long products, and is associated with concepts such as oil and gas exploration and state-owned enterprise reform [1].

Core Viewpoint - Jinlong Electromechanical has shown a significant increase in stock price and financial performance, indicating potential growth opportunities in the electronic components sector [1][2]. Financial Performance - As of September 30, Jinlong Electromechanical achieved a revenue of 1.212 billion yuan, representing a year-on-year growth of 14.32% [2]. - The net profit attributable to the parent company for the same period was 29.6625 million yuan, marking a substantial increase of 149.28% year-on-year [2]. - The company's stock price has increased by 19.96% year-to-date, with a recent 5-day increase of 2.85% and a 20-day increase of 5.66% [1]. Stock Market Activity - The stock price of Jinlong Electromechanical rose by 2.46% to 5.41 yuan per share, with a trading volume of 29.6333 million yuan and a turnover rate of 0.69% [1]. - The company has seen a net inflow of main funds amounting to 84,900 yuan, with large orders accounting for 2.33% of total purchases [1]. - Jinlong Electromechanical has appeared on the "Dragon and Tiger List" once this year, with a net purchase of 68.7741 million yuan on May 8 [1]. Company Overview - Jinlong Electromechanical, established on November 11, 1993, and listed on December 25, 2009, is located in Dongguan, Guangdong Province [1]. - The company's main business includes the research, production, and sales of motors, silicone plastic structural components, and touch display products [1]. - The revenue composition of the company is as follows: structural components 48.45%, touch display modules 39.14%, motors 10.31%, electronic atomizers and related accessories 1.16%, and others 0.95% [1]. Shareholder Information - As of September 30, the number of shareholders for Jinlong Electromechanical was 41,600, a decrease of 9.11% from the previous period [2]. - The average circulating shares per person increased by 10.03% to 19,327 shares [2]. Dividend Information - Since its A-share listing, Jinlong Electromechanical has distributed a total of 311 million yuan in dividends, with no dividends paid in the last three years [3].

Group 1 - The stock price of Renmin Tongtai dropped by 2.00% on November 26, trading at 11.74 CNY per share, with a total market capitalization of 6.808 billion CNY [1] - Year-to-date, Renmin Tongtai's stock price has increased by 56.53%, but it has seen a decline of 26.39% over the last five trading days [1] - The company has appeared on the "Dragon and Tiger List" 13 times this year, with the most recent appearance on November 21, where it recorded a net buy of -7.5568 million CNY [1] Group 2 - Renmin Tongtai Pharmaceutical Co., Ltd. was established on February 19, 1994, and is primarily engaged in pharmaceutical wholesale, retail, and medical services [2] - The company's revenue composition includes 57.72% from wholesale to medical clients, 22.26% from wholesale to commercial clients, and 18.91% from retail [2] - As of September 30, the number of shareholders increased to 27,700, with an average of 20,900 circulating shares per shareholder [2] Group 3 - Renmin Tongtai has distributed a total of 1.671 billion CNY in dividends since its A-share listing, with 83.504 million CNY distributed in the last three years [3]

资料显示，浙江帅丰电器股份有限公司位于浙江省绍兴市嵊州市经济开发区五合西路100号，成立日期 1998年12月15日，上市日期2020年10月19日，公司主营业务涉及以集成灶为核心的新型智能厨房电器的 研发、设计、生产和销售业务。主营业务收入构成为：集成灶62.63%，其他厨房用品17.72%，木质橱 柜9.42%，再生铜7.89%，其他(补充)2.35%。 帅丰电器所属申万行业为：家用电器-厨卫电器-厨房电器。所属概念板块包括：小盘、电子商务、QFII 持股、家用电器、新零售等。 11月26日，帅丰电器盘中下跌2.10%，截至09:48，报16.35元/股，成交2013.97万元，换手率0.67%，总 市值29.99亿元。 资金流向方面，主力资金净流出353.67万元，特大单买入0.00元，占比0.00%，卖出155.08万元，占比 7.70%；大单买入220.24万元，占比10.94%，卖出418.84万元，占比20.80%。 帅丰电器今年以来股价涨30.64%，近5个交易日涨1.81%，近20日涨5.42%，近60日涨2.57%。 今年以来帅丰电器已经3次登上龙虎榜，最近一次登上龙虎榜为7月17日。 机 ...